Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 1956; 9: 822–30.
Leger-Ravet MB, Peuchmaur M, Devergne O, Audouin J, Raphael M, Van Damme J et al. Interleukin-6 gene expression in Castleman's disease. Blood 1991; 178: 2923–30.
Schur PH. Clinical features of SLE. WN Kelly, ED Harris, S Ruddy, CB Sledge, editors. In: Textbook of Rheumatology, 4th ed. Philadelphia: W.B. Saunders Company 1993: 1017–42.
Frizzera G. Castleman's disease and related disorders. Semin Diag Pathol 1988;5:346–64.
Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972; 29: 670–83.
Diebold J, Tulliez M, Bernadou A, Audouin J, Tricot G, Reynes M et al. Angiofollicular and plasmacytic polyadenopathy: a pseudotumourous syndrome with dysimmunity. J Clin Pathol 1980; 33: 1068–76.
Yoshizaki K, Kuritani T, Kishimoto T. Interleukin-6 in autoimmune disorders. Semin Immunol 1992; 4: 155–66.
Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: Clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985; 3: 1202–16.
Petersen BA, Frizzera G. Multicentric Castleman's disease. Semin-Oncol 1993; 20: 634–47.
Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989; 74: 1360–67.
Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, et al. Jagannath, S. Brief report: Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleuin-6 antibody. N Eng J Med 1994; 330: 602–5.
Brandt SJ, Bodline DM, Dunbar MB, Dunbar CE, Nienhuis AW. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 1990; 86: 592–99.
Tang B, Matsuda T, Akira S, Nagata N, Ikehara S, Hirano T et al. Age-associated increase in interleukin-6 in MRL/lpr mice. Int Immunol 1991; 3: 273–8.
Krishnan J, Danon AD, Frizzera G. Reactive lymphadenopathies and atypical lymphoproliferative disorders. Am J Clin Pathol 1993; 99: 385–96.
Bradwick PA, Zvaifler NJ, Gill GN, Newman D, Greenway GD, Resnik DL. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: The POEMS syndrome. Medicine 1980; 59: 311–22.
Nakanishi T, Sobue I, Toyokura Y, Nishitani H, Kuroiwa Y, Satoyoshi E, Tsubaki T, et al. The Crow-Fukase syndrome: A study of 102 cases in Japan. Neurology 1984; 34: 712–20.
Takatsuki K, Yodoi J, Uchiyama T, Sagawa K. Plasma cell dyscrasia with polyneuropathy and endocrine disorder: Review of 36 patients. Neurol Med 1977; 7: 483–93.
Mandler RN, Kerrigan DP, Smart J, Kuis W, Villiger P, Lotz M. Castleman's disease in POEMS a syndrome with elevated interleukin-6. Cancer 1992; 69: 2697–2703.
Adelman HM, Cacciatore ML, Pascual JF, Mike JM, Alberts WM, Wallach PM. Case report: Castleman's disease in association with POEMS. Am J Med Sci 1994; 307: 112–14.
Miralles GD, O'Fallon JR, Talley NJ. Plasma-cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome. N Engl J Med 1992; 327: 1919–23.
Hosaka S, Kondo H. Three cases of Castleman's disease mimicking the features of collagen disease. Ryumachi 1994; 34: 42–47.
Nanki T, Tomiyama J, Arai S. Mixed connective tissue disease associated with multicentric Castleman's disease. Scand J Rheumatol 1994; 23: 215–17.